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Introduction. 177Lu-OPS201 is a high-anity somatostatin receptor subtype 2 antagonist for PRRT in patients with neuroen-
docrine tumors. ­e aim is to nd the optimal scaling for dosimetry and to compare the biokinetics of 177Lu-OPS201 in animals
and humans.Methods. Data on biokinetics of 177Lu-OPS201 were analyzed in athymic nude Foxn1nu mice (28 F, weight: 26 ± 1 g),
Danish Landrace pigs (3 F-1 M, weight: 28 ± 2 kg), and patients (3 F-1 M, weight: 61 ± 17 kg) with administered activities of
0.19–0.27MBq (mice), 97–113MBq (pigs), and 850–1086MBq (patients). After euthanizing mice (up to 168 h), the organ-specic
activity contents (including blood) were measured. Multiple planar and SPECT/CT scans were performed until 250 h (pigs) and
72 h (patients) to quantify the uptake in the kidneys and liver. Blood samples were taken up to 23 h (patients) and 300 h (pigs). In
pigs and patients, kidney protection was applied. Time-dependent uptake data sets were created for each species and organ/tissue.
Biexponential ts were applied to compare the biokinetics in the kidneys, liver, and blood of each species. ­e time-integrated
activity coecients (TIACs) were calculated by using NUKFIT. To determine the optimal scaling, several methods (relative mass
scaling, time scaling, combined mass and time scaling, and allometric scaling) were compared. Results. A fast blood clearance of
the compound was observed in the rst phase (<56 h) for all species. In comparison with patients, pigs showed higher liver
retention. Based on the direct comparison of the TIACs, an underestimation in mice (liver and kidneys) and an overestimation in
pigs’ kidneys compared to the patient data (kidney TIAC: mice  1.4 h, pigs  7.7 h, and patients  5.8 h; liver TIAC: mice  0.7 h,
pigs  4.1 h, and patients  5.3 h) were observed. Most similar TIACs were obtained by applying time scaling (mice) and combined
scaling (pigs) (kidney TIAC: mice  3.9 h, pigs  4.8 h, and patients  5.8 h; liver TIAC: mice  0.9 h, pigs  4.7 h, and patients 
5.3 h). Conclusion. If the organ mass ratios between the species are high, the combined mass and time scaling method is optimal to
minimize the interspecies di¤erences. ­e analysis of the t functions and the TIACs shows that pigs are better mimicking
human biokinetics.
1. Introduction
Recently, the radiolabeled somatostatin receptor subtype 2
(SST2) agonists DOTA-[Tyr3]octreotate (DOTATATE),
DOTA-[Tyr3]octreotide (DOTATOC), and DOTA-[NaI3]
octreotide (DOTANOC), as well as the antagonists OPS201
(DOTA-JR11) and OPS202 (NODAGA-JR11), have been
used for imaging and treatment of neuroendocrine tumors
(NETs) which are overexpressing the somatostatin receptor
SST2 [1–5].
Previous preclinical and clinical studies have indicated
that radiolabeled SST2 antagonists are superior to the
corresponding agonists especially for tumor targeting de-
spite little to no internalization in tumor cells [1, 3, 5–7].
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A possible explanation for this observation is that the an-
tagonistic peptides are independent of the somatostatin
receptor activation state (G-protein phosphorylation);
therefore, they utilize more binding sites on the tumor cell
surface, have a lower dissociation rate, and also have longer
tumor retention than agonistic peptides [8]. It was also
shown that the uptake in the tumor is higher for SST2
antagonists compared to SST2 agonists [1, 3–5, 8]. ,e
absorbed dose to the kidneys, the main organ at risk after
treatment of NETs with DOTA labeled compounds [9], was
around 50% higher for the antagonist as compared to the
agonist 177Lu-octreotate [5].
Rodents are the most frequently used species in pre-
clinical studies. However, larger animals such as pigs or dogs
are expected to mimic humans’ physiology better than ro-
dents [2]. In addition, these larger animals can be scanned
several times with a human SPECT/CT under the same
conditions as patients. ,erefore, these studies have the
advantage of long follow-up times and showed that multiple
blood samples can be taken for dosimetry and metabolism
assessment similar to patient studies.
Until today, there is one clinical human study (by Wild
et al. [5]), two preclinical mouse model studies (by Dalm
et al. [7] and by Nicolas et al. [3]), and one preclinical pig
study (by Beykan et al. [2]) with 177Lu-DOTA-JR11
(OPS201) focusing on biodistribution and dosimetry
[2, 3, 5, 7]. In all of these studies, the main focus was on
biodistribution and dosimetry. In the clinical study [5], the
dosimetry of four patients with advanced NETwas analyzed
and compared to 177Lu-DOTATATE. In the preclinical
study by Dalm et al. [7], tumor-xenografted mice were used
to determine the optimal dosage for therapy, and the
therapeutic eﬀect of 177Lu-OPS201 (177Lu-DOTA-JR11) was
compared to the eﬀect of 177Lu-DOTA-octreotate. ,e
follow-up period of the experiments was short (4 time points
up to 7 d after injection) for a quantiﬁcation of the bio-
distribution and dosimetry. In another preclinical study on
mice by Nicolas et al. [3], OPS201 labeled with 177Lu, 90Y,
and 111In was compared with the 177Lu-DOTATATE.
Neither time-integrated activity coeﬃcient (TIAC) values
nor absorbed dose values were published; only the relative
administered activity values per gram were reported. ,e
focus of the preclinical pig study by Beykan et al. [2] was on
in vivo biodistribution and dosimetry in pigs. Five pigs (four
with coadministered amino acids and one without kidney
protection) were analyzed; TIAC, absorbed dose, and ef-
fective dose coeﬃcients values were reported.
For dose calculations, none of the preclinical studies
accommodated methods for considering the diﬀerences in
physiology between animals and humans. For this purpose,
extrapolation methods are used that are based on mathe-
matical equations in order to predict TIACs and conse-
quently absorbed doses in humans by using data collected
from animals. Mostly, these techniques are needed for
predicting the absorbed doses for a ﬁrst application of a
radiopharmaceutical in humans [10]. As of today, there is no
systematic study that analyzes the diﬀerence in biokinetics of
radiopharmaceuticals dedicated to therapy between animal
models and patients. In total, there are ﬁve published
interspecies extrapolation methods related to the use of
radionuclides [10, 11] in preclinical studies. However, there
are no studies related to either comparing extrapolation
methods or optimizing a scaling method.
,erefore, the aim of this work is to compare the in vivo
biokinetics of 177Lu-OPS201 in two animal models (mice
and pigs) and in patients for the liver, kidneys, and blood. In
addition, all published extrapolation methods related to the
use of radionuclides (“scaling methods”) were examined to
ﬁnd the optimal method for analyzing biokinetics and
dosimetry.
2. Methods
OPS201 was synthesized and 177Lu-OPS201 was prepared for
mice as described in the study by Nicolas et al. (for mice [3]),
by Beykan et al. (for pigs [2]), and byWild et al. (for humans
[5]).
For analyzing the biokinetics of 177Lu-labeled peptides in
preclinical and clinical studies, the data of 177Lu-OPS201
athymic nude Foxn1nu mice (28 females, weight: 26 ± 1 g,
age: 8–9 weeks) [3], Danish Landrace pigs (3 females-1 male,
weight: 28 ± 2 kg, age: 3 months) [2], and patients (3 females-
1 male, weight: 61 ± 17 kg, age: 44–77 years) [5] with ad-
ministered activities of 0.19–0.27MBq (mice, 0.017 µg of
peptide), 97–113MBq (pigs, 9 µg of peptide), and 850–
1086MBq (patients, 55–106 µg of peptide) were included.
For pigs and patients, kidney protection was applied.
After administration of 177Lu-OPS201, blood samples
were taken up to 72 h for mice, up to 300 h for pigs, and up to
23 h for patients in order to measure the blood radioactivity
contents by using the same well-type gamma counter
(Packard Instruments). ,e human blood data were, orig-
inally, provided as relative values, normalized to the ﬁrst
blood sample immediately taken after injection. In order to
convert the raw count values to blood uptake values per mL
human blood in each time point, human blood data were
quantiﬁed (in Bq/mL) retrospectively by using the same
calibration factor as for the mouse study. As the data showed
high variability, the median values of all mice and patients
were used for further processing.
2.1. Image Acquisition and Reconstruction for Liver and
Kidneys
2.1.1. For Pigs. After injection, multiple whole body (WB)
planar images and SPECT/CT scans were acquired at 0.5, 2,
3, 4, 50, 100, 150, and 250 h to quantify the uptake in the
kidneys and liver. SPECT/CT data and WB planar images
were acquired using Symbia T16 (Siemens AG). ,e ac-
quisition duration was 50min for all scans: 10min for WB
and 40min for SPECT (2 bed positions of 20min each). In
addition, a 5min CT was performed for attenuation cor-
rection. For reconstruction, CT-based attenuation correc-
tion and triple energy window-based scatter corrections
were applied. ,e images were reconstructed with the
FLASH 3D iterative reconstruction algorithm with 6 iter-
ations and 6 subsets. ,e resulting images were smoothed
with a 6mm Gauss ﬁlter.
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2.1.2. For Patients. SPECT/CT data and WB planar images
were generated with the Philips BrightView XCT equipped
with a medium-energy, parallel-hole collimators SPECT/CT
scanner.WB scans and low-dose SPECT/CTwere performed
at 1, 3, 24, and 72 h after 975MBq mean administered ac-
tivity of 177Lu-OPS201. ,e acquisition duration was 43min
for all scans: 17min for WB and 26min for SPECT (2 bed
positions of 13min each). In addition, a CT was performed
for attenuation correction. For reconstruction, CT-based
attenuation correction and triple energy window-based
scatter corrections were applied. ,e images were recon-
structed with the Astonish (Philips) iterative reconstruction
algorithm with 4 iterations and 16 subsets.
2.2. Dosimetry Analysis
2.2.1. Quantiﬁcation of Activity and Integration of the Time-
Activity Curves. To quantify the amount of activity, the av-
erage percentage values corresponding to the injected radio-
activity (A%) per organ as a function of timewere calculated for
the liver, right kidney, left kidney, and blood for each species via
a manual VOI analysis (for pigs and patients) and via gamma
counter (for mice). For pigs, all VOIs were drawn based on the
CT scan. In order to avoid spill-out eﬀects, CT-based organ
VOIs were enlarged as matching 2 voxels plus their actual CT-
based volumes. For mice, scariﬁed organs were counted by
using the well-type gamma counter, total numbers of count
values for the selected organs (kidneys and liver) were reported,
and A% values were calculated. ,e time-activity curves of
blood for each species were analyzed separately from the
collected samples. Since the scan times of pigs were not exactly
identical to those of all animals, the population-based A%
values of pigs were used to create the time-activity curves for
both selected organs and blood. For the mice and humans,
since all scanning time points were identical in each study and
the standard deviations in each time point are less than 5% (as
is shown in the supplementary ﬁle), meanA%values for organs
and median A% values for blood were used.
To analyze the interspecies diﬀerences in biokinetics of
177Lu-OPS201, the time-dependent uptake data sets for the
kidneys, liver, and blood were used, and individual ﬁts
(TACs) for each species including optimal ﬁt function pa-
rameters by using the software solution NUKFIT [12] were
created. ,e resulting ﬁts were investigated to compare the
biokinetics of the diﬀerent species.
,e organ TIACs were calculated by integration of the
mean (for mice and humans) and population-based (for
pigs) time-dependent uptake data sets using NUKFIT [12],
choosing the optimal ﬁt functions as proposed by the code.
,e TIACs are estimated by analytically integrating the ﬁtted
functions. ,eir standard error values are determined as-
suming Gaussian error propagation (can be seen in Sup-
plementary Table 1). For this investigation, a systematic
error in activity quantiﬁcation of 10% was assumed for each
measured data point.
2.3. Extrapolation Methods. ,ere are several extrapolation
approaches that are used to estimate TIAC values, absorbed
doses, and in vivo biokinetics and biodistribution in humans
based on animal data. Assuming the same biodistribution in
animals and humans is one of the most commonly used
methods, which means applying no extrapolation. In ad-
dition to this, relative mass scaling, time scaling, allometric
scaling, and the combined relative mass and time scaling are
the other techniques described in the literature; however,
there is no common well-accepted method.
In this study, ﬁve interspecies extrapolation methods
were applied on blood TIAC values (only for pigs) and
kidneys and liver TIAC values (for mice and pigs) and
examined to determine the optimal method for dosimetry
[10, 13]. None of the extrapolation method could be applied
on blood TIAC values of mice since the data for the total
animal blood volume were not available.
Method 1 (equation (1)) (“same biodistribution ap-
proach”) is based on the assumption that the TIACs for the
same organ in an animal and human are the same [10].
Method 2 (equation (2)) is relative mass scaling in which the
TIAC value of a human organ is set equal to the TIAC value
of the same animal organ multiplied by the ratio of WB and
the selected organ mass of the human and animal. Method 3
(equation (3)) is time scaling in which time is scaled by a
power function of the ratio of WB masses of the human and
animal for calculating the TIACs. In Method 3, the exponent
is set to 0.25 [10]. Method 4 is a combined method: ﬁrst time
scaling is applied (equation (3)) and then the TIAC values of
the animal are scaled based on relative mass scaling
(equation (2)) [10]. Method 5 (equation (4)) applies allo-
metric scaling in which TIACs of an animal are scaled by a
power function of the ratio of WB masses of the human and
animal. In this method, the exponent depends on the se-
lected organ and is set equal to 0.92 for the liver and 0.82 for
the kidneys [13]:
TIAC organhuman � TIAC organanimal, (1)
TIAC organhuman � TIAC organanimal
×
morgan/mWB( )human
morgan/mWB( )animal
,
(2)
torganhuman � torgananimal
×
mWB( )human
mWB( )animal
[ ]
1/4
,
(3)
TIAC organhuman � TIAC organanimal
×
mWB( )human
mWB( )animal
[ ]
[b−1]
,
(4)
where m � mass, WB � whole body, t � time, b � scaling
component, b (for liver) � 0.92, and b (for kidneys) � 0.85.
3. Results
3.1. Biodistribution and Dosimetry Calculations.
Calculated lambda values used to create the TACs by using
the optimal ﬁt function parameters from NUKFIT for each
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species and organ are shown in Supplementary Table 1. ,e
respective species-dependent time-activity curves based on
VOI and well-type gamma counter analysis for the kidneys,
liver, and blood are displayed in Figures 1–3. Dots represent
time-dependent percentage uptake data sets for the selected
organs and blood, while lines represent individual ﬁts
(TACs) including ﬁt function parameters from NUKFIT for
the selected organs and blood in each species. Kidneys, liver,
or blood ﬁt curves including ﬁt functions were named using
the ﬁrst letter of the kidneys, liver, or blood such as for mice
(KM, LM, or BM), pigs (KP, LP, or BP), or humans (KH, LH,
or BH), respectively. Since a logarithmic scale was used in all
ﬁgures for better visualization, the error bars cannot be
distinguished in total. However, all standard deviation
values were less than 10% (shown in Supplementary
Tables 2(a) and 2(b)). A fast blood clearance of the com-
pound is observed in the ﬁrst phase (largest half-life: 1.83 h;
Supplementary Table 1) for each species. 10min after in-
jection, less than 5% of the injected activity per milliliter of
blood circulates in pigs and humans (Figure 3). Overall, the
blood clearance of OPS201 in pigs and humans was faster
compared to mice.
,e best approximation for the last phase of the liver
curves for pigs and humans was a monoexponential func-
tion. However, the liver decay function in mice has biex-
ponential characteristics. ,e slope of the last phase was
lower than the corresponding function of pigs and humans.
In comparison to patients, pigs show higher liver retention
(Figure 2). As for kidneys, the shapes of curves for each
species were similar (Figure 1).
,e resulting TIACs based on extrapolation methods
are summarized in Tables 1 and 2. Applying Method 1
(same biodistribution approach) to the mice data for both
kidneys and liver resulted in underestimation by a factor
of 4 for the kidneys and a factor of 7 for the liver compared
to the patient data (kidney TIAC: mice � 1.4 h and patients
� 5.9 h; liver TIAC: mice � 0.7 h and patients � 5.3 h). On
the contrary, since pigs mimic humans better as compared
to mice, Method 1 in pigs results in a slight overestimation
for the kidneys and a slight underestimation for the liver
by a factor of 1.3 (kidney TIAC: pigs � 7.7 h and patients �
5.9 h; liver TIAC: pigs � 4.1 h and patients � 5.3 h).
Most similar TIACs were obtained by applying time
scaling (Method 3) and combined relative mass and time
scaling (Method 4) methods (kidney TIAC: mice � 3.9 h,
pigs � 4.8 h, and patients � 5.9 h; liver TIAC: mice � 0.9 h,
pigs � 4.7 h, and patients � 5.3 h; Table 2). Other methods
showed higher deviations.
,e kidney TIAC values of mice (except the results after
applying Method 3) are underestimated approximately
fourfold in Method 1 and Method 4, and they are over-
estimated twelvefold byMethod 2 (relative mass scaling) and
Method 5 (allometric method). In contrast to the mouse
data, the kidney TIAC values of pigs did not show high levels
of variations; the data are overestimated 1.2–1.6 times in
Method 1, Method 3, and Method 5.
For mice liver TIAC values despite of the scaling, even
when applying Method 3, underestimations approximately
by a factor of 6 (in Method 3) up to 17 (in other methods)
were observed. For pigs liver TIAC values, only in Method 2
and Method 4, underestimations approximately by a factor
of 5 were calculated; other applied methods show similar
results.
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Figure 1: Time-activity curves of the kidneys based on VOI and well-
type gamma counter analysis for each species. Dots: time-dependent
percentage uptake data sets for the kidneys. Line: ﬁt curves for the
kidneys including ﬁt function parameters fromNUKFITformice (KM),
pigs (KP), and humans (KH), respectively. All standard deviation values
were less than 10% (can be seen in Supplementary Tables 2(a) and 2(b)).
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Figure 2: Time-activity curves of the liver based on VOI and well-type
gamma counter analysis for each species. Dots: time-dependent per-
centage uptake data sets for the liver. Line: ﬁt curves for the liver in-
cluding ﬁt function parameters fromNUKFITformice (LM), pigs (LP),
and humans (LH), respectively. All standard deviation values were less
than 10% (can be seen in Supplementary Tables 2(a) and 2(b)).
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4. Discussion
In this study, the in vivo biokinetics of 177Lu-OPS201 for
three species (mice, pigs, and humans) in the liver, kid-
neys, and blood were compared by using well-type gamma
counter measurements and multiple WB planar and
SPECT/CT images. In addition to this, all applicable
scaling methods in the literature were summarized in
order to identify an appropriate extrapolation method
that minimizes the interspecies diﬀerences for comparing
biokinetics, in vivo biodistribution, and dosimetry.
Observed interspecies diﬀerences in the ﬁtted curves used
to investigate the biokinetics show the necessity of scaling.
Five interspecies extrapolation methods were tested on the
kidneys and liver of both species (mice and pigs) and also on
blood data of pigs. Our results show that all applied scaling
methods, except time scaling (Method 3), result in a weight-
dependent decrease of TIAC values and, consequently, the
absorbed doses. Instead of Method 1, when the organ mass
ratios between the species are high (e.g., for mice compared to
humans), the scalingmethod either 3 or 4 should be applied to
predict in vivo biokinetics, dosimetry, and absorbed doses in
humans based on animal data more accurately. On the
contrary, in small animals like mice, despite the applied
extrapolation methods, interspecies diﬀerences may still be
observed. For instance, in our study, none of the applied
extrapolation methods on mice liver TIAC values provides
similar values compared to humans due to the biphasic
clearance of the OPS201 agent from the mice liver which was
diﬀerent compared to pigs and humans.
Although mouse models are applied widely in cancer
translational research, there are still some limitations that
need to be addressed [14]. Amongst others, the main dif-
ferences in physiological parameters are the organ size, the
heartbeat rate, and, as a consequence, the faster biological
half-life of radioactive compounds in the animals [14]. In
addition, gender-speciﬁc diﬀerences may play a role; how-
ever, the setup of the studies was not optimized to address
these potential eﬀects.
Allometric scaling may account partially for some of
these eﬀects as we have shown in our study (equation (4);
Method 5). However, as de Jong and Maina stated [14], it is
advisable to remain “critical and cautious about the appli-
cability of animal data to the clinical domain.”
Not only scaling but also the follow-up period plays an
important role when investigating the biokinetics of ther-
apeutic agents. In this study, the follow-up time in mice and
patients was rather short, especially for an analysis of the
biokinetics and dosimetry. ,e blood samples were taken
from 1 h up to 72 h for mice and from 0.3 h up to 23 h for
patients. We are missing the early phase (for mice) and late
phase (for mice and humans) of the biokinetics. ,ese data
at early time points provide valuable information of the
uptake pattern of the radiopharmaceutical, whereas for
biodistribution and dosimetry assessments of 177Lu-labeled
compounds, the late time points (72 hours and later) have
the greatest impact on the TIAC values which directly aﬀect
also the absorbed dose values [15]. In order to have suﬃcient
data leading to more accurate results for analyzing the
biokinetics and dosimetry, blood sampling at least up to
150–200 h is needed. As observed for blood, additional data
on both early time points and late time points are needed for
a better analysis of the liver and kidney biokinetics in mice
and patients, despite the fact that the patterns in each species
were similar.
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Figure 3: Time-activity curves of blood based on VOI and well-type
gamma counter analysis for each species. Dots: time-dependent per-
centage uptake data sets for the blood. Line: ﬁt curves for the blood
including ﬁt function parameters from NUKFIT for mice (BM), pigs
(BP), and humans (BH), respectively. All standard deviation valueswere
less than 10% (can be seen in Supplementary Tables 2(a) and 2(b)).
Table 1: Time-integrated activity coeﬃcient (TIAC (unit: h)) values
for the selected organs of mice, pigs, and humans with respective error
calculated by NUKFIT with an assumption of 10% systematic error
based on Method 1 (same biodistribution approach).
Kidney
TIAC ± error
(h)
Liver
TIAC ± error
(h)
Blood
TIAC ± error
(ml/h)
Method 1
Mice 1.44 ± 8.5E − 02 0.75 ± 4.1E − 02 0.0370 ± 2.0E − 03
Pigs 7.67 ± 1.8E − 01 4.08 ± 9.4E − 02 0.0002 ± 3.4E − 06
Humans 5.85 ± 4.2E − 01 5.32 ± 3.4E − 01 0.0002 ± 8.2E − 05
Table 2: Time-integrated activity coeﬃcient (TIAC (unit: h))
values for the selected organs of mice and pigs based on applied
scaling methods.
Kidney
TIAC (h)
Liver TIAC
(h) Blood TIAC (h/ml)
Mice Pigs Mice Pigs Pigs
Method 2 0.43 4.17 0.32 1.04 0.00022
Method 3 3.89 8.73 0.88 4.65 0.00025
Method 4 1.17 4.75 0.38 1.18 0.00026
Method 5 0.44 6.63 0.40 3.78 0.00021
Method 2: relative mass scaling; Method 3: time scaling; Method 4:
combined relative mass and time scaling; Method 5: allometric scaling.
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Since the follow-up time of blood in mice and humans
was not suﬃcient and, additionally, because of high vari-
ability in the median values for humans andmice blood data,
mice blood data were neglected from the extrapolation
method analyses. In addition, there is a lack of information
about the total blood volume of mice; thus, the uptake of the
radiopharmaceutical cannot be deduced. On the contrary,
since we do not have these limitations in pigs, ﬁve ex-
trapolation methods were applied on the pig blood data set.
In addition to this, in pigs, measurements could be carried
out over a longer period for dosimetry, biokinetics, and
biodistribution assessments of therapeutic agents as com-
pared to rodents, which makes the analyses more stable and
accurate.
Since the kidneys and bone marrow are critical organs in
177Lu-OPS201 treatment, applying our results to calculate
bone marrow-absorbed doses could potentially improve the
study analyses. Bone marrow dosimetry can be performed
either on the basis of blood and whole body TIACs [16, 17]
image based on scans of lumbar vertebrae 2–4 (LV2–4) [18].
As we have neither data for mice on the activity contents of
bone marrow containing tissues nor LV2–4-segmented
uptake values for the patients, a comparison of bone marrow
dosimetry based on images (for humans) and on bone
marrow uptake values (for mice) could not be performed.
For the blood-based method, the main contributor to the
bone marrow-absorbed dose is the TIAC of the blood
([16, 17]) which we have compared in our work. For future
studies, it could be beneﬁcial to have bone marrow tissue
samples and/or corresponding image data for an improved
comparison of bone marrow TIACs and, as a consequence,
absorbed doses.
,e fast blood clearance of the OPS201 in the ﬁrst phase
(<56 h) for each species was in agreement with studies of the
agonist [15, 19]. Sandstrom et al. [15] observed a ﬁrst phase
with a mean eﬀective half-life of 1.6 h, in agreement with our
data for mice (1.8 h) and pigs (1.7 h). For humans, most likely
because of the short observation period, the value was lower
(0.5 h). For the late phase in pigs, our result (58 h) is also
close to the results obtained in the human study with the
agonist (43 h). Part of an ongoing phase 1 study [20] with
177Lu-OPS201 in patients with SSTR-positive progressive
NETs, in which dosimetry data are taken also at time points
later than 48 h, is to substantiate whether the biokinetics of
the agonist and antagonist in the pig model are comparable
to those in the patients after treatment with 177Lu-OPS201.
5. Conclusion
Extrapolation methods need to be applied in preclinical
studies in order to predict the biokinetics, TIACs, absorbed
doses, and dosimetry in humans more accurately. According
to our results, if the organ mass ratios between the species
are high (e.g., for mice compared to humans), the most
adequate scaling method for TIACs is either time scaling or
combination of relative mass and time scaling. Furthermore,
this study shows that, for the 177Lu-labeled dosimetry
studies, follow-up times at late time points (more than 72 h)
are needed for TIAC calculations in order to appropriately
represent the area under the curve and to analyze both
biokinetics and dosimetry accurately. Based on our analysis
of the biokinetics, ﬁt functions, and the TIAC values, pigs
mimic humans better than mice. In addition to all of these
topics mentioned above, increasing the number of subjects
and including a gender-based analysis of biokinetics and
dosimetry may produce even more representative results.
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